2021
Facility-Level Variation in Use of Locoregional Therapy for Metastatic Prostate Cancer
Buck M, Ghiraldi E, Demkowicz P, Park H, An Y, Kann B, Yu J, Sprenkle P, Kim I, Leapman M. Facility-Level Variation in Use of Locoregional Therapy for Metastatic Prostate Cancer. Urology Practice 2021, 9: 141-149. PMID: 37145694, DOI: 10.1097/upj.0000000000000290.Peer-Reviewed Original ResearchMetastatic prostate cancerLocal therapyProstate cancerLocoregional therapyFacility-level useFacility-level variationM1 prostate cancerDefinitive local therapyNational Cancer DatabaseMetastatic prostate adenocarcinomaClinical practice guidelinesMultilevel logistic regressionM1 diseasePatient factorsTherapy useUninsured statusRadical prostatectomyCancer DatabaseProstate adenocarcinomaHigh comorbidityLocal treatmentPatient levelPractice guidelinesLower oddsPatients
2016
Genomic predictors of biochemical failure following radical prostatectomy.
Aneja S, Yu J, Glazer P. Genomic predictors of biochemical failure following radical prostatectomy. Journal Of Clinical Oncology 2016, 34: 114-114. DOI: 10.1200/jco.2016.34.2_suppl.114.Peer-Reviewed Original ResearchPathologic T stageGleason 7 diseaseBiochemical failureRadical prostatectomyT stageProstate adenocarcinomaClinical dataPredictors of BFAggressive regional therapyClinical patient characteristicsPre-treatment PSARNA expressionStratification of patientsHierarchical logistic regression modelsLogistic regression modelsMedian followAggressive therapyPatient characteristicsCancer Genome AtlasExpression of TP53Gleason 7Median ageRegional therapyGleason scoreClinical correlates